Hui Jiang

Hui Jiang

Auto-generated profile, based on publicly available information

Hui Jiang

Department of Pathology, Changhai Hospital, Shanghai, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Radiology
Verified
Journal Article
Closed access
YBYun Bian
Yun Bian
ZZZhilin Zheng
Zhilin Zheng
XFXu Fang
Xu Fang
HJHui Jiang
Hui Jiang
MZMengmeng Zhu
Mengmeng Zhu
CSChengwei Shao
Chengwei Shao
An artificial intelligence model outperformed radiologists and clinical and radiomics models for prediction of lymph node metastasis at CT in patients with pancreatic ductal adenocarcinoma. Background Although deep learning has brought revolutionary changes in health care, reliance on manually selected cross-sectional images and segmentation remain methodological barriers. Purpose To ...



1 August 2021 in Clinical Imaging
Verified
Journal Article
Closed access
YBYun Bian
Yun Bian
HJHui Jiang
Hui Jiang
KCKai Cao
Kai Cao
XMXu Fang Mms
Xu Fang Mms
JLJing Li
Jing Li
JLJianping Lu
Jianping Lu

15 February 2021
Verified
Conference Paper
Closed access
CYChangxing Yang
Changxing Yang
HXHuide Xiang
Huide Xiang
YBYun Bian
Yun Bian
JLJianping Lu
Jianping Lu
HJHui Jiang
Hui Jiang
JZJianming Zheng
Jianming Zheng
SPIE Digital Library Proceedings

28 October 2026 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
CCChengwei Chen
Chengwei Chen
JYJieyu Yu
Jieyu Yu
YSYixuan Shen
Yixuan Shen
DZDanqun Zheng
Danqun Zheng
YZYilun Zheng
Yilun Zheng
YBYun Bian
Yun Bian
Purpose To develop and evaluate an interpretable CT spatial phenotype associated with extrapancreatic perineural invasion (EPNI) in resected pancreatic ductal adenocarcinoma. Materials and Methods This multicenter study included training, internal testing, neoadjuvant testing, retrospective external testing, prospective external testing, and The Cancer Imaging Archive (TCIA) sets. The Preoperative Risk of Perineural High-risk Extension in Tumors (PROPHET) model and threshold were locked before testing. Performance was assessed with area under the receiver operating characteristic curve (AUC) and threshold metrics. Six radiologists compared unaided and assisted readings. A stratified Cox model related PROPHET risk to survival, adjusting for age, sex, tumor size, carbohydrate antigen 19-9, nodal category, and differentiation. Results Among 1854 patients (median age, 63 years; 1131 male), AUCs were 0.92 (95% CI, 0.86–0.96) in prospective external testing, 0.85 (95% CI, 0.75–0.93) in retrospective external testing, 0.90 (95% CI, 0.83–0.95) after neoadjuvant therapy, 0.99 (95% CI, 0.98–> 0.99) in internal testing, and 0.80 (95% CI, 0.68–0.93) in TCIA. TCIA sensitivity and specificity were 24/30 (80%) and 2/19 (11%). Assistance increased mean sensitivity to 93% from 82% and reduced reading time to 3.02 from 3.64 minutes per patient (both Holm-adjusted P < .001). Higher PROPHET risk was associated with shorter survival (adjusted hazard ratio, 1.95; 95% CI, 1.53–2.47; nominal P < .001). Conclusion PROPHET provides a CT-visible tumor-vessel spatial phenotype associated with pathologically confirmed EPNI. © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license.